ACTUALIZACIÓN SOBRE BIOMARCADORES TEMPRANOS DE INFARTO AGUDO DE MIOCARDIO Y SU RELACIÓN CON LA TROPONINA CARDÍACA: UNA REVISIÓN DE LA LITERATURA
DOI:
https://doi.org/10.47820/recima21.v5i8.5497Palabras clave:
Síndrome coronario agudo, sensibilidad y especificidad de los biomarcadores, isquemia miocárdica, diagnóstico precoz del IAMResumen
Antecedentes: Las enfermedades cardiovasculares son responsables de la mayoría de muertes en el mundo, por lo tanto, las causas más comunes de muerte y, por lo tanto, se debe prestar atención a este tipo de manifestación clínica, ya que alrededor del 10% de los dos pacientes que recibieron terapia torácica para alivio inmediato fueron diagnosticados con infarto agudo de miocardio (IAM). Objetivo: Este estudio tiene como objetivo analizar los principales biomarcadores previos al infarto agudo de miocardio. Metodología: Se trata de una Revisión Descriptiva de la Literatura, realizada utilizando la base de datos del Portal Capes. Los descriptores utilizados son: [adulto hipertenso] Y [nuevos biomarcadores] Y [sensibilidad] O [especificidad] Y [diagnóstico precoz] Y [infarto agudo de miocardio]. Resultado: la troponina requiere mediciones repetidas para un diagnóstico conciso; La CK-MB tiene una sensibilidad cercana al 40% y una especificidad del 90%; La copeptina alcanza niveles plasmáticos máximos de 0 a 1 hora después del inicio de dos síntomas. El miARN tuvo una especificidad del 82% y una sensibilidad del 78%. La mioglobina parece tener baja especificidad y alta sensibilidad, lo que no favorece el diagnóstico. Los neutrófilos y las células plasmáticas migran al área isquémica. La albúmina y la H-FABP tienen alta sensibilidad y especificidad. Conclusión: Los marcadores bioquímicos de infarto analizados, troponina, CK-MB, copeptina, miRNA, H-FABP, Myo, neutrófilos y células plasmáticas, y albúmina, no obtuvieron un excelente parámetro no diagnóstico cuando se analizaron por separado por ellos. , observamos la correlación entre dos indicadores y el pronóstico del IAM.
Descargas
Citas
Tilea I, Varga A, Serban RC. Past, present, and future of blood biomarkers for the diagnosis of acute myocardial infarction-promises and challenges. Diagnostics (Basel). 2021 May 15;11(5):881. DOI: https://doi.org/10.3390/diagnostics11050881
Shi C, Xie H, Ma Y, Yang Z, Zhang J. Nanoscale technologies in highly sensitive diagnosis of cardiovascular diseases. Front Bioeng Biotechnol. 2020 Jun 5:8:531. DOI: https://doi.org/10.3389/fbioe.2020.00531
Tscherny K, Kienbacher C, Fuhrmann V , Schreiber W, Herkner H1, Roth D. Early identification of patients with chest pain at very low risk of acute myocardial infarction using clinical information and ECG only. Int J Clin Pract. 2020 Aug;74(8):e13526. DOI: https://doi.org/10.1111/ijcp.13526
Lavallaz JDFD, Prepoudis A, Wendebourg MJ, Kesenheimer, Kyburz D, Daikeler T et al. Skeletal muscle disorders: a noncardiac source of cardiac troponin T. Circulation. 2022 Jun 14;145(24):1764-1779.
Yang Y, Gao S, Fang Q, Yang J. Diagnostic value of Copeptin combined with hypersensitive cardiac troponin T detection in early acute myocardial infarction: a protocol of randomized double-blind diagnostic trial. Medicine (Baltimore). 2021 Jan 8;100(1):e23949. DOI: https://doi.org/10.1097/MD.0000000000023949
Hua Sun J, Kum Liu X, Wei Xing X, Yang Y, Xuan HH, Fu BB. Value of Cardiac Troponin, Myoglobin Combined with Heart-type Fatty Acid-binding Protein Detection in Diagnosis of Early Acute Myocardial Infarction. Pak J Med Sci. 2023 Nov-Dec;39(6):1690-1694. DOI: https://doi.org/10.12669/pjms.39.6.7101
Jeong JH, Seo YH, Ahn JY, Kim KH; Seo JY; Chun, KY et al. Performance of copeptin for early diagnosis of acute myocardial infarction in an emergency department setting. Ann Lab Med. 2020 Jan;40(1):7-14. DOI: https://doi.org/10.3343/alm.2020.40.1.7
Chaulin A. Cardiac troponins: contemporary biological data and new methods of determination. Vasc Health Risk Manag. 2021 Jun 3:17:299-316. DOI: https://doi.org/10.2147/VHRM.S300002
Lee CC, Huang SS, Yeo YH, Hou, YT, Park JY, Inoue K, Hsu WT. High-sensitivity-cardiac troponin for accelerated diagnosis of acute myocardial infarction: a systematic review and meta-analysis. Am J Emerg Med. 2020 Jul;38(7):1402-1407. DOI: https://doi.org/10.1016/j.ajem.2019.11.035
Chaulin AM. Cardiac troponins: current information on the main analytical characteristics of determination methods and new diagnostic possibilities. Medwave. 2021 Dec 10;21(11):e8498. DOI: https://doi.org/10.5867/medwave.2021.11.002132
Westwood ME, Armstrong N, Worthy G, Fayter D, Ramaekers BLT, Grimm S et al. Optimizing the use of high-sensitivity troponin assays for the early rule-out of myocardial infarction in patients presenting with chest pain: a systematic review. Clin Chem. 2021 Jan 8;67(1):237-244. DOI: https://doi.org/10.1093/clinchem/hvaa280
Szarpak L, Lapinski M, Gasecka A, Pruc M, Drela WL, Koda M, et al. Performance of Copeptin for Early Diagnosis of Acute Coronary Syndromes: A Systematic Review and Meta-Analysis of 14,139 Patients. J Cardiovasc Dev Dis. 2021 Dec 27;9(1):6. DOI: https://doi.org/10.3390/jcdd9010006
De Jongh FW, Pouwels S, De Jongh MC, Dubois EA, Schaik RHNV. The Predictive Power of the 14–51 Ng/L High Sensitive Troponin T (hsTnT) Values for Predicting Cardiac Revascularization in a Clinical Setting. J Clin Med. 2022 Dec 1;11(23):7147. DOI: https://doi.org/10.3390/jcm11237147
Mi X, Li H, Tu Y. An Aptamer Biosensing Strategy for Label-Free Assay of Dual Acute Myocardial Infarction Biomarkers Built upon AuNPs/Ti3C2-MXenes. Chemosensors 2023;11(3):157. DOI: https://doi.org/10.3390/chemosensors11030157
Kulshrestha MR, Raj A, Tiwari V, Chandra S, Tiwari BC, Jha A. Evaluation of dual marker approach using heart-type fatty acid binding protein and high sensitivity troponin-I as an alternative to serial sampling for diagnosis of acute myocardial infarction. EJIFCC. 2022 Apr 11;33(1):43-55.
Kim KS, Suh GJ, Song SH, Jung YS, Kim T, Shin SM, et al. Copeptin with high-sensitivity troponin at presentation is not inferior to serial troponin measurements for ruling out acute myocardial infarction. Clin Exp Emerg Med. 2020 Mar;7(1):35-42. DOI: https://doi.org/10.15441/ceem.19.013
Lalitha SS, Sankar A, Purushothaman G, Sridevi C. Diagnostic Accuracy of Heart-type Fatty Acid Binding Protein for the Detection of Acute Myocardial Infarction among South Indian Population: A Cross-sectional Study. National Journal of Laboratory Medicine, 2023 Jan;12(1):BO17-BO19 DOI: https://doi.org/10.7860/NJLM/2023/58374.2659
Hu C, Ma L, Guan M, Mi F, Peng F, Guo C, et al. SERS-based magnetic immunoassay for simultaneous detection of cTnI and H-FABP using core–shell nanotags. Analytical Methods, 2020 Dec 7;12(45):5442-5449. DOI: https://doi.org/10.1039/D0AY01564D
Hinton J, Mariathas M, Gabara L, Nicholas Z, Allan R, Ramamoorthy S, et al. Distribution of contemporary sensitivity troponin in the emergency department and relationship to 30-day mortality: The CHARIOT-ED substudy. Clinical Medicine, 2020 Nov;20(6):528-534. DOI: https://doi.org/10.7861/clinmed.2020-0267
Habib, SMS, Khan AR, Habib S, Ullah SZ, Sultana R, Tariq QD, et al. Role of heart fatty acid binding protein in early detection of non ST-elevation myocardial infarct and its comparison with other cardiac markers. JPMA. The Journal of the Pakistan Medical Association, 2021 Jan;71(1(B)):233-238. DOI: https://doi.org/10.47391/JPMA.270
Wang B, Li Y, Hao X, Yang J, Han X, Li T et al. Comparison of the clinical value of miRNAs and conventional biomarkers in AMI: a systematic review. Frontiers in genetics, 2021 Jun 17:12:668324. DOI: https://doi.org/10.3389/fgene.2021.668324
Mansouri F, Mohammadzad MHS. Molecular miR-19a in acute myocardial infarction: novel potential indicators of prognosis and early diagnosis. Asian Pacific Journal of Cancer Prevention: APJCP. Apr. 2020;21(4):975. DOI: https://doi.org/10.31557/APJCP.2020.21.4.975
Chen L, Bai J, Liu J, Lu H, Zheng K. A four-microRNA panel in peripheral blood identified as an early biomarker to diagnose acute myocardial infarction. Frontiers in Physiology, 2021 Jul 7:12:669590. DOI: https://doi.org/10.3389/fphys.2021.669590
Pan X, He Y, Chen Z, Yan G, Ma G. Circulating miR-130 is a potential bio signature for early prognosis of acute myocardial infarction. Journal of Thoracic Disease, 2020 Dec;12(12):7320-7325. DOI: https://doi.org/10.21037/jtd-20-3207
Wang J, Xu L, Tian L, Sun Q. Circulating microRNA-208 family as early diagnostic biomarkers for acute myocardial infarction: A meta-analysis. Medicine, 2021 Dec 23;100(51):e27779. DOI: https://doi.org/10.1097/MD.0000000000027779
Bobusoglu O, Balci S, Gundes A, Camsari A, Tamer L. Investigation into miRNA profile in patient groups with and without ST elevation. Turkish Journal of Biochemistry, 2023;48(2):203–208. DOI: https://doi.org/10.1515/tjb-2021-0282
Almandlawi SG, Ali AM. The efficiency of cardiac biomarkers in the identification of patients with acute coronary syndrome. Zanco Journal of Medical Sciences (Zanco J Med Sci), 2020 Aug;24(2). DOI: https://doi.org/10.15218/zjms.2020.020
Wang L, Wu M, Ma J, Ma Z, Liang J, Tao N, et al. Development of a point-of-care test based on selenium nanoparticles for heart-type fatty acid-binding proteins in human plasma and blood. International Journal of Nanomedicine, 2022 Mar 22:17:1273-1284. DOI: https://doi.org/10.2147/IJN.S359541
John RV, Devasiya T, Nidheesh VR, Adigal S, Lukose J, Kartha VB, Chidangil S. Cardiovascular biomarkers in body fluids: progress and prospects in optical sensors. Biophysical Reviews, 2022 Aug 18;14(4):1023-1050. DOI: https://doi.org/10.1007/s12551-022-00990-2
Chiesa M, Piacentini L, Bono E, Milazzo V, Campodonico J, Marenzi G, Colombo GI. Whole blood transcriptome profile at hospital admission discriminates between patients with ST-segment elevation and non-ST-segment elevation acute myocardial infarction. Scientific Reports, 2020 May 26;10(1):8731. DOI: https://doi.org/10.1038/s41598-020-65527-7
Guclu K, Celik M. Prognostic value of inflammation parameters in patients with non-ST elevation acute coronary syndromes. Angiology, 2020 Oct;71(9):825-830. DOI: https://doi.org/10.1177/0003319720936500
Özbiçer S, Kalkan GY, Urgun OD, Neselioglu S, Erel O. Ischemia modified albumin levels in distinguishing NSTEMI patients from non-ischemic controls and correlation with disease severity. Cukurova Medical Journal, 2021 Dec;46(4):1566-1573. DOI: https://doi.org/10.17826/cumj.976875
Descargas
Publicado
Cómo citar
Número
Sección
Categorías
Licencia
Derechos de autor 2024 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.